Shifting Care in Acute Leukemia: The Dawn of Menin Inhibition
Menin inhibitors revumenib and ziftomenib target key leukemia-driving mutations, improving remission rates, enabling transplant opportunities, and advancing precision treatment for relapsed acute leukemias.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.